.jpg)
Apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. Our lead drug candidate APG101 has demonstrated a statistically significant efficacy in a controlled phase II trial in recurrent glioblastoma.
Gene expression profiles in genome instability-based classes of colorectal cancer, BMC Cancer
Gene expression profiles in genome instability-based classes of colorectal cancer, BMC Cancer
Preclinical Candidates ǀ Apogenix
Epsilogen announces significant expansion of management team with three new senior hires
Apalis Evaluation Board
Volunteer Board Management Software - BoardSpace
Apogee - VJ Electronix
10 Easy Steps – Deleting a Point from a Qualified Building Management System (BMS)
Stronghold Games Terraforming Mars Ares Expedition Card Game Collectors Edition, Board Games - Canada
Regulatory chromatin rewiring promotes metabolic switching during adaptation to oncogenic receptor tyrosine kinase inhibition
Volunteer Board Management Software - BoardSpace
Maximum Apocalypse Review
Apogee Products - Visionca
